Alzheimer's Talks

A free teleconference series offered by UsAgainstAlzheimer's covering a wide range of topics with leaders in the Alzheimer's community. If you're interested in sponsoring a call, email hjameson@usagainstalzheimers.org.

Latest Talks

Thumbnail
October 4, 2018

In Search of a Way to Inhibit Tau - Prof. Claude Wischik

Tangles of the protein tau in the brain are known to be a sign of Alzheimer’s, but research seeking an Alzheimer’s treatment has long been more focused on the amyloid build-up that occurs.

For 30 years, Professor Claude Wischik, co-founder and executive chairman of TauRx Therapeutics, along with his colleagues at the University of Aberdeen, has explored the structure and role of tau in the development of Alzheimer’s and...

Alzheimer's Talks
August 24, 2018

The Latest & Best in Alzheimer's Research - Daisy Duarte, Dr. Tabassum Majid, Dr. Yakeel Quiroz

In July, at the world’s largest gathering of Alzheimer’s researchers, the 2018 Alzheimer’s Association International Conference (AAIC), thousands of researchers gathered to discuss the latest and best in Alzheimer’s research. What does the latest research have to say about disparities in Alzheimer’s and dementia impacting diverse communities? What were the most relevant developments for those living with Alzheimer’s and their care partners?

For our August Alzheimer’s Talk, two internationally renowned...

Thumbnail
July 31, 2018

Can We Each Take Steps to Reduce Alzheimer's Risk? Dr. Laura Baker

Is there anything each of us can do to protect our cognitive function or even reduce our risk of Alzheimer’s? Just as we have found ways to reduce heart disease risk, scientists increasingly think there may be steps we can take to ward off Alzheimer’s.

Globally renowned researcher Dr. Laura Baker of the Wake Forest School of Medicine discusses the U.S. POINTER study, which she is leading and is enrolling...

Thumbnail
June 20, 2018

What Matters Most in a Potential Treatment- Dr. Brett Hauber

Does research into new Alzheimer's treatments reflect what matters most to those living with the disease and to their care partners? When new drugs become available, will they make the changes in people’s lives that are most important to them—or only help people do better on cognitive tests but not improve ability in areas of day-to-day living that are most important?

Surprisingly, patient and caregiver priorities have not been studied in a...